Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRACTBACKGROUND: Alphacalcidol, a vitamin D analog, shows immune regulatory potency as it works on the macrophage and T cell to control inflammation and T cell dysregulation in elderly. None has been known about its effect on elderly with various states of frailty syndrome, which have different level of chronic low grade inflammation. This study aimed to determine the effect of alphacalcidol on inflammatory cytokines (IL-6, IL-10, g-IFN ) and T cell subsets (CD4/CD8 ratio and CD8+ CD28-) of elderly with various stages of frailty syndrome. METHODS: from January to July 2017, a double blind randomized controlled trial (RCT) with allocation concealment, involving 110 elderly subjects from Geriatric Outpatient Clinic Cipto Mangunkusumo Hospital Jakarta, was conducted to measure the effect of 0.5 mcg alphacalcidol administration for 90 days to inflammatory cytokines (IL-6, IL-10, g-IFN) from PBMC culture supernatant, as well as CD4/CD8 and CD8+CD28- percentage using flow cytometry. Statistical analysis using SPSS version 20 was performed with t-test to measure mean difference. RESULTS: of 110 subjects involved in the RCT consisting of 27 fit, 27 pre-frail and 56 frail elderly, 25(OH)D serum level was found to be as low as 25.59 (12.2) ng/ml in alphacalcidol group and 28.27 (10.4) ng/ml in placebo group. Alphacalcidol did not decrease IL-6 (p=0.4) and g- IFN (p=0.001), but it increased IL-10 (p=0,005) and decreased IL6/IL10 ratio (p=0.008). Alphacalcidol increased CD4/CD8 ratio from 2.68 (SD 2.45) to 3.2 (SD 2.9); p=0.001 and decreased CD8+ CD28- percentage from 5.1 (SD 3.96) to 2.5 (1.5); p<0.001. Sub group analysis showed similar patterns in all frailty states. CONCLUSION: Alphacalcidol improves immune senescence by acting as anti-inflammatory agent through increased IL-10 and decreased IL6/IL-10 ratio and also improves cellular immunity through increased CD4/CD8 ratio and decreased CD8+ CD28- subset in elderly. This effect is not influenced by frailty state."

"Latar belakang : Kejadian jatuh yang tinggi pada usia lanjut berhubungan erat dengan penurunan kekuatan otot. Seiring bertambahnya usia terjadi sarkopenia dimana massa otot berkurang sebesar 1-2% setiap tahun dan menyebabkan penurunan kekuatan otot sebesar 3%. Vitamin D mempunyai aksi biologis pada otot sehingga menjadi salah satu modalitas terapi sarkopenia. Walaupun peran vitamin D pada kekuatan otot masih kontroversial, namun studi sebelumnya menunjukkan analog vitamin D (alfacalcidol) dapat meningkatkan kekuatan otot dengan memakai luaran kekuatan otot ekstremitas bawah.Tujuan : Menentukan pengaruh alfacalcidol terhadap kekuatan otot ekstremitas atas yang diukur dengan pemeriksaan kekuatan genggam tangan pada perempuan usia lanjut Indonesia.Metode : Studi ini merupakan uji klinis acak tersamar ganda yang dilakukan selama bulan April-September 2012 di poliklinik Geriatri RS. Cipto Mangunkusumo, Jakarta. Subjek penelitian adalah perempuan berusia ≥ 60 tahun dengan kekuatan genggam tangan £ 22 kg yang diukur dengan dinamometer. Subjek dirandomisasi dalam dua kelompok yaitu kelompok yang menerima alfalcalcidol 1x0,5 mg dan kelompok kontrol menerima plasebo. Masing-masing kelompok mendapat kalsium laktat 500 mg dan diamati selama 90 hari. Pada akhir penelitian dilakukan pemeriksaan kekuatan genggam tangan.Hasil : Sebanyak 122 subjek direkrut, namun terdapat 27 subjek yang mempunyai kriteria eksklusi sehingga randomisasi membagi 95 subjek masing-masing 47 subjek pada kelompok alfacalcidol dan 48 subjek pada kelompok plasebo. Sebanyak 88 subjek menyelesaikan penelitian hingga akhir (7 drop out) dan dianalisis dengan uji Mann Whitney. Terdapat perbedaan peningkatan kekuatan otot yang bermakna antara kelompok alfacalcidol dibanding kelompok plasebo (15,50 kg vs. 13,75 kg ; p= 0,003).Kesimpulan: Analog vitamin D (alfacalcidol) dapat meningkatkan kekuatan otot perempuan usia lanjut Indonesia yang mempunyai kekuatan genggam tangan yang rendah dibandingkan pemberian plasebo.

---

Background : The age-related increase in falls is strongly associated with a decline in muscle strength. Sarcopenia develops in concomitant with aging, where muscle mass decrease 1-2% annually, lead to 3% reduction in muscle strength. Vitamin D was known to have a biological action on muscle, so it was used as one of the therapy for sarcopenia. Although the role of vitamin D on muscle strength was still controversial, previous studies in vitamin D analog (alfacalcidol) reveal a promising effect in lower extremity muscle strength.Objective : To determine the effect of alfacalcidol on upper extremities muscle strength in elderly ambulatory Indonesian women.Methods : This was a randomized, double-blind clinical trial, which was conducted at Geriatrics Outpatient Clinic of Cipto Mangunkusumo General Hospital Jakarta, during April to September of 2012. The study subject consists of elderly women (aged ≥60 years old) with handgrip strength of ≤ 22 kg, measured with a handheld dynamometer. Subject was then randomized to two groups, one receiving alfacalcidol 1x0.5 mcg and the other receiving identically packaged placebo. Each group also received 500mg calcium lactate daily and then was observed for 12 weeks. At the end of the observation period, a second measurement of handgrip by using handheld dynamometer was performed.Outcome : A total 122 subjects were enrolled in this study. There were 95 subjects fulfilled the eligible criteria consist of 47 subjects receiving alfacalcidol and 48 subjects as a control. A number of 88 subjects were able to complete the intervention period and then the results were analyzed with Mann Whitney test. The study showed a significant increase of muscle strength in the intervention group compared to placebo (15.50 kg vs. 13.75 kg; p = 0.003).Conclusion : Daily doses of 0.5 mg alfacalcidol significantly improved muscle strength in elderly Indonesian women with low handgrip strength compared to placebo."

"ABSTRAKTerapi metformin berpotensi untuk memperbaiki sindrom frailty dengan memodifikasi resistensi insulin, inflamasi, dan konsentrasi miostatin.Penelitian ini bertujuan untuk mengkaji peran metformin terhadap kekuatan genggam tangan, kecepatan berjalan, konsentrasi miostatin serum, dan kualitas hidup terkait kesehatan pada pasien usia lanjut dengan pre-frail.Uji klinis acak tersamar ganda dilakukan pada pasien rawat jalan berusia 60 tahun dengan status pre-frail yang direkrut secara konsekutif Maret 2015 ndash;Juni 2016 di RSCM. Pasien dieksklusi bila menyandang diabetes melitus, skor Geriatric Depression Scale ge; 10, skor Abbreviated Mental Test < 8, fase akut penyakit, dan kontraindikasi terhadap metformin. Evaluasi luaran penelitian dilakukan sebelum dan pasca-intervensi selama 16 minggu.Randomisasi terhadap 120 subjek menempatkan 60 subjek untuk tiap kelompok perlakuan. Sebanyak 43 subjek kelompok metformin 3 x 500 mg dan 48 subjek kelompok plasebo menyelesaikan penelitian. Terdapat peningkatan kecepatan berjalan yang bermakna dengan rerata sebesar 0,39 0,77 detik atau 0,13 0,24 meter/detik pada kelompok metformin dan tetap bermakna setelah dilakukan penyesuaian terhadap faktor prognostik penting yang tidak setara p = 0,024 . Pada analisis ITT ada tidaknya peningkatan kecepatan berjalan > 0,1 meter/detik didapatkan ARR 8,3 IK95 -7,9 ndash;24 , dengan NNT sebesar 12. Tidak terdapat perbedaan bermakna kekuatan genggam tangan, konsentrasi miostatin serum, dan kualitas hidup terkait kesehatan antara kedua kelompok perlakuan. Konsentrasi miostatin serum berkorelasi negatif lemah r = -0,247; p = 0,018 dengan kecepatan berjalan, namun tidak berkorelasi dengan kekuatan genggam tangan. Skor indeks EQ-5D berkorelasi positif sedang dengan kecepatan berjalan r = 0,566; p = 0,000 dan berkorelasi positif lemah dengan kekuatan genggam tangan r = 0,355; p = 0,001.Sebagai simpulan, pemberian metformin 3 x 500 mg selama 16 minggu secara statistik dan klinis bermakna dalam meningkatkan kecepatan berjalan sebagai salah satu dimensi kualitas hidup terkait kesehatan, namun belum dapat meningkatkan skor indeks EQ-5D, tidak meningkatkan kekuatan genggam tangan, dan belum menurunkan konsentrasi miostatin serum.Kata kunci. kecepatan berjalan, kekuatan genggam tangan, kualitas hidup terkait kesehatan, metformin, miostatin, pre-frail, usia lanjut.

---

ABSTRACT

Metformin is considered to have potential effects to improve frailty syndrome by modifying insulin resistance, inflammation, and myostatin serum level.

This study aimed at investigating the effect of metformin on handgrip strength, gait speed, myostatin serum level, and health related quality of life HR QoL in pre frail elderly.

A double blind randomized controlled trial was conducted on elderly outpatients aged 60 years and older with pre frail status consecutively recruited from March 2015 to June 2016 at Cipto Mangunkusumo Hospital. Patients with history of diabetes mellitus, Geriatric Depression Scale score ge 10, Abbreviated Mental Test score 8, acute phase of diseases, and contraindication s to metformin were excluded. The measurement of study outcomes was conducted at baseline and after 16 weeks of intervention.

One hundred twenty subjects were randomized and equally assigned into metformin 3 x 500 mg or placebo group. There were 43 subjects in metformin group and 48 subjects in placebo group completed the intervention. The mean gait speed in metformin group significantly improved by 0.39 0.77 second or 0.13 0.24 meter second, even after adjusted for importance prognostic factors p 0,024 . Intention to treat analysis on the presence or absence of increased gait speed 0.1 meter second showed ARR 8.3 95 CI 7.9 ndash 24 , with NNT of 12. There were no significant differences on handgrip strength, myostatin serum level, and HR QoL between the two intervention groups. Myostatin serum level had weak negative correlation with gait speed r 0.247 p 0.018 , but did not correlate with handgrip strength. EQ 5D index had moderate positive correlation with gait speed r 0.566 p 0.000 and weak positive correlation with handgrip strength r 0.355 p 0.001.

In conclusion, metformin 3 x 500 mg for 16 weeks significantly improved gait speed as one of the HR QoL dimensions, but not significantly improved the EQ 5D index score and handgrip strength nor decreased myostatin serum level.

Keywords. gait speed, handgrip strength, health related quality of life, metformin, myostatin, pre frail, elderly."

"scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels."

"Background: sarcopenia contributes to the development of frailty syndrome. Frailty syndrome is potentially improved by modifying insulin resistance, inflammation, and myostatin level. This study is aimed to investigate the effect of metformin on handgrip strength, gait speed, myostatin serum level, and health related quality of life (HR-QoL) among non diabetic pre frail elderly patients.Methods: a double blind randomized controlled trial study was conducted on non-diabetic elderly outpatients aged >60 years with pre frail status based on phenotype and/ or index criteria (Cardiovascular Health Study and/ or Frailty Index 40 items) consecutively recruited from March 2015 to June 2016 at Cipto Mangunkusumo Hospital. One hundred twenty subjects who met the research criteria were randomized and equally assigned into 3 x 500 mg metformin or placebo group. The study outcomes were measured at baseline and after 16 weeks of intervention.Results: out of 120 subjects, 43 subjects in metformin group and 48 subjects in placebo group who completed the intervention. There was a significant improvement on the mean gait speed of metformin group by 0.39 (0.77) second or 0.13 (0.24) meter/second that remained significant after adjusting for important prognostic factors (p = 0.024). There was no significant difference on handgrip strength, myostatin serum level, and HR QoL between both groups.Conclusion: 3 x 500 mg metformin for 16 weeks was statistically significant and clinically important in improving usual gait speed as one of the HR QoL dimensions, but did not significantly improve the EQ 5D index score, handgrip strength, nor myostatin serum level."

"ABSTRAKLatar belakangBerbagai studi terdahulu melaporkan bahwa alfacalcidol mampu meningkatkan kekuatan otot, keseimbangan dan signifikan dalam menurunkan kejadian jatuh pada ras Kaukasia. Namun belum ada penelitian yang membuktikan peran alfacalcidol terhadap mobilitas fungsional pada ras Asia.TujuanMengetahui pengaruh pemberian alfacacidol 0,5 µg selama 90 hari terhadap mobilitas fungsional dasar perempuan usia lanjut di Indonesia.MetodeDilakukan uji klinis acak tersamar ganda pada bulan April-September 2012 terhadap 95 pasien perempuan usia lanjut di Poliklinik Geriatri RS Cipto Mangunkusumo Jakarta, Indonesia. Subyek dibagi menjadi kelompok yang mendapat alfacalcidol dan kalsium 500 mg sehari sekali selama 90 hari dan kelompok yang mendapat plasebo dan kalsium 500 mg. Dilakukan uji timed-up and Go Test (TUG) pada awal dan akhir penelitian. Dilakukan analisis per protokol dan uji Mann-Whitney untuk melihat perbedaaan mobilitas fungsional pada kedua kelompok setelah intervensi.Hasil95 subyek dirandomisasi dan dibagi menjadi dua kelompok, terdiri dari 48 subyek yang mendapat plasebo dan 47 subyek mendapat alfacalcidol. Setelah tiga bulan pengamatan didapatkan perbaikan waktu uji TUG yang signifikan pada kedua kelompok (2,49 vs 1,83 detik; p<.0001). Terdapat perbaikan waktu uji TUG yang signifikan dari kelompok alfacalcidol dibandingkan dengan kelompok plasebo (9,01 vs.10,07 detik; p = 0.028).KesimpulanAlfacalcidol dengan dosis 0,5 µg satu kali per hari selama 90 hari terbukti mampu meningkatkan mobilitas fungsional dasar pada perempuan usia lanjut Indonesia.

---

ABSTRACTBackgroundPrevious studies reported the D-analog alfacalcidol, increases muscle power and balance and lead to a highly significant decreases in the number of fallers and falls in Caucasian elderly community-dwelling population.ObjectiveTo determine the effect of alfacalcidol on functional mobility in Indonesian elderly women community-dwelling population.MethodsA randomized, double-blind controlled trial was conducted in elderly women subjects geriatric clinic of Cipto Mangunkusumo National Hospital Jakarta Indonesia on April-September 2012. Intervention group was given 0,5 mcg alfacalcidol and 500 mg calcium daily for 90 days and another group was given placebo and 500 mg calcium. Balance test, Timed-up and Go Test (TUG) was measured at the beginning and after 3 months. Per protocol analysis to functional mobility after intervention between the two groups was performed.Results95 subjects were fulfiling study criteria and randomized into 2 groups, containing 47 subjects in alfacalcidol group and 48 subjects in placebo group. Both groups were comparable in all important prognostic factors including age, BMI, nutritional status, muscle strength. After three months the mean time in alfacalcidol group used for the TUG was decrease significantly by 2,49 s (p<.0001). There were significant improvement of the median time for TUG in the group that received alfacalcidol compared to placebo (9,01 vs.10,07 p = 0.028).ConclusionTreatment with 0.5 mg alfacalcidol with calcium effectively improved functional mobility in Indonesian elderly women."

"Background: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin sulfate. However, there are controversies whether glucosamine chondroitin sulfate or their combination with methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome of glucosamine chondroitin sulfate (GC), glucosamine chondroitin sulfate methylsulfonylmethane (GCM), and placeboin patients with knee osteoarthritis (OA) Kellgren Lawrence grade I II. Methods: a double blind, randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren Lawrence grade I II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, then at 4th, 8th and 12th week after treatment. Results: on statistical analysis it was found that at the 12th week, there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on WOMAC score (p=0.01) and VAS score (p<0.001). Comparing the score difference between weeks, WOMAC score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 (p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and week 12 (p<0.001). Conclusion: combination of glucosamine chondroitinsulfate methylsulfonylmethane showed clinical benefit for patients with knee OAK ellgren Lawrence grade I II compared with GC and placebo. GC did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I II."

"Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse effects such as myopathy and liver dysfunction. NC120 is herbal lipid lowering drug containing red yeast rice (RYR) extract, guggulipid, and chromium picolinate, and expected to have better safety profile. The aim of this study was to evaluate the efficacy and safety profiles of NC120 in lowering blood lipid. Methods: this was a double blind randomized clinical trial comparing NC120 with placebo in subjects with hypercholesterolemia. Two capsules of NC120 or placebo were administered twice a day for 28 days. Blood total-cholesterol, LDL-cholesterol, and triglyceride were measured on day-0, day-7, and day-28. Unpaired t-test was used to compare study parameter between groups, and one-way ANOVA was used to compare within group. Results: 25 subjects received NC120 and 24 subjects received placebo. Significant decrease of total cholesterol and LDL-cholesterol were observed since day-7 in NC120 group, while the changes in placebo group were not significant at all time of observation. No significant decrease of triglyceride was observed in NC120 group and in placebo group. Side effects were minor and comparable between the two groups. Conclusion: NC120 is effective in reducing total cholesterol and LDL-cholesterol, but not triglyceride. This drug shows a good safety profile, and thus can be considered for patients who can not tolerate statin drugs."

"ABSTRAKLatar Belakang: Alfacalcidol, sebuah vitamin D analog, potensial bermanfaat memperbaiki imunosenesens pada pasien usia lanjut dengan sindrom frailty karena bekerja sebagai anti inflamasi melalui Vitamin D Receptor VDR pada makrofag dan sel TTujuan: Mengkaji efek pemberian alfacalcidol in vitro dan in vivo terhadap perubahan sitokin inflamasi IL-6, IL-10 dan Interferon g serta subset limfosit T rasio CD4/CD8, persentase sel T CD 8 CD28- dari kultur Peripheral Blood Mononuclear Cell PBMC dan Immune Risk Profile IRP pada usila dengan sindrom frailtyMetode: Selama Januari sampai Juli 2017 di RS Cipto Mangunkusumo Jakarta, direkrut masing-masing 8 orang subyek usila fit, pre-frail dan frail dan 10 subyek dewasa sehat sebagai kontrol. Pada 34 subyek ini dinilai perubahan kadar IL-6, IL-10 dan IFN g yang diukur dengan kit ELISA dari supernatan kultur PBMC 24 jam yang distimulus Lipopolisakarida LPS 100 ng/ml dengan dan tanpa pretreatment alfacalcidol in vitro. Selain itu juga dilakukan uji klinis acak tersamar ganda dengan pemberian alfacalcidol 0,5 mcg 90 hari pada 110 subyek berusia lanjut lalu diamati perubahan kadar IL-6, IL-10 dan IFN , g perubahan rasio CD4/CD8 dan persentase sel T CD8 CD28- serta penilaian Immune Risk Profile. Dilakukan uji t tidak berpasangan untuk mengetahui perbedaan rerata kadar sitokin dan persentase populasi sel T dan uji chi square untuk menilai beda proporsi subyek dengan IRP positif.Hasil: Pada penelitian in vitro didapatkan rerata kadar 25 OH D serum yang semakin menurun seiring dengan perburukan status frailty. Alfacalcidol in vitro tidak menurunkan IL-6 dan IFN g, namun meningkatkan IL-10 pada seluruh kelompok. Dari uji klinis didaparkan alfacalcidol 0,5 mcg selama 90 hari tidak menurunkan IL-6 p=0,4 dan IFN gamma p=0,001 , namun mampu meningkatkan IL-10 p=0,005 dan menurunkan rasio IL6/IL10 p=0,008 . Alfacalcidol meningkatkan rasio CD4/CD8 dari 2,68 SB 2,45 menjadi 3,2 SB 2,9 ; p=0,001 dan menurunkan persentase CD8 CD28- dari 5,1 SB 3,96 menjadi 2,5 1,5 ; p

---

ABSTRACTIntroduction Chronic low grade inflammation and dysregulation of cellular immunity are the cardinal signs of immunosenescence in elderly with frailty syndrome. Alphacalcidol, a vitamin D analog shows immunoregulatory potency as it works on the macrophage and T cell, to control inflammation and T cell dysregulation in the elderly.Objective to determine the effect of alphacalcidol on inflammatory cytokines IL 6, IL 10, IFN gamma and T cell subsets CD4 CD8 ratio and CD8 CD28 and Immune Risk Profile of the elderly with frailty syndromeMethods During January to August 2017, in vitro study was conducted involving 10 healthy adults volunteer and 8 elderly each in fit, pre frail and frail category from Outpatient Clinics of Cipto Mangunkusumo Hospital Jakarta Indonesia using 24h Peripheral Blood Mononuclear Cells PBMC culture supernatants to determine the change of IL 6, IL 10 and g IFN level measured by ELISA, following stimulation with Lipopolisaccharide LPS 100 nm, with and without pretreatment with alphacalcidol. A double blind randomized controlled trial RCT with allocation concealment, involving 110 elderly subjects was also conducted to measure the effect of 0,5 mcg alphacalcidol administration for 90 days on inflammatory cytokines IL 6, IL 10, g IFN from 24 h PBMC culture supernatant, as well as CD4 CD8 and CD8 CD28 count and change of Immune Risk Profile. Statistical analysis was performed using t test to measure mean difference of cytokines and T cell count and chi square to measure proportion difference of IRP.Result In vitro study using PBMC showed alphacalcidol administration did not decrease IL 6 level IL p 0,24 and g IFN p 0,36 , but it increased IL 10 p 0,02 . Of 110 subjects involved in the RCT consisting of 27 fit elderly, 27 pre frail elderly and 56 frail elderly, it can be observed that Alphacalcidol 0,5 mcg for 90 did not decrease IL 6 p 0,4 and g IFN p 0,001 , but increased IL 10 p 0,005 and decrease IL6 IL10 ratio p 0,008 . Alphacalcidol increased CD4 CD8 ratio from 2,68 SD 2,45 to 3,2 SD 2,9 p 0,001 and decrease CD8 CD28 percentage from 5,1 SD 3,96 to 2,5 1,5 p"

"Hipertensi merupakan penyakit kardiovaskular yang paling umum dan paling banyak diderita, terutama oleh lanjut usia (lansia). Beberapa penelitian menunjukkan vitamin D berperan dalam tekanan darah. Pada lansia kadar 25(OH)D menurun karena kurangnya paparan sinar matahari dan asupan makanan yang mengandung vitamin D. Kekurangan vitamin D dapat dicegah, salah satunya dengan suplementasi. Penelitian ini merupakan penelitian eksperimental dengan desain uji acak terkendali tersamar ganda pada lansia di Panti Sosial Tresna Werdha Budi Mulia 1 bulan April sampai Juni 2023 dengan tujuan menganalisis pengaruh suplementasi vitamin D terhadap kadar 25(OH)D dan tekanan darah. Kadar 25(OH)D serum diperiksa menggunakan metode Chemiluminescent Immunoassay (CLIA), tekanan darah diperiksa menggunakan sphygmomanometer digital. Suplementasi diberikan 1 kali perhari selama 8 minggu, untuk kelompok kontrol diberikan plasebo sedangkan untuk kelompok perlakuan diberikan vitamin D dengan dosis 2000IU (subjek Insufisiensi) dan 4000IU (subjek defisiensi). 62 subjek penelitian berusia 60-89 tahun (median 67 tahun) ikut serta dalam penelitian ini dan terbagi secara random menjadi 30 subjek kelompok kontrol dan 32 subjek kelompok perlakuan. Peningkatan kadar 25(OH)D pada kelompok kontrol 23 ± 4,87 ng/mL menjadi 27,3 ± 7,34 ng/mL (p=0,000), pada kelompok perlakuan 17,9 ± 4,38 ng/mL menjadi 36,07 ± 9,84 ng/mL (p=0,000). Analisis rerata perubahan menunjukkan bahwa suplementasi vitamin D meningkatkan kadar 25(OH)D secara bermakna (D = 4,2 ± 2,47 ng/mL pada kelompok kontrol dan D = 18,17 ± 5,46 ng/mL pada kelompok perlakuan; p = 0.000). Penurunan tekanan darah sistolik pada kelompok kontrol 133,9(121 – 159,5) mmHg menjadi 129,3(96 – 159) mmHg (p=0,027), pada kelompok perlakuan 135,3(121 - 180) mmHg menjadi 126(101 - 153) mmgHg (p=0,000). Penurunan tekanan darah diastolik pada kelompok kontrol 89,6(80 - 105) mmHg menjadi 82,4(64 - 103) mmHg (p=0,000), pada kelompok perlakuan 89,2(81,5 – 98,5) mmHg menjadi 80,8 (67 – 90) mmHg (p=0,000). Akan tetapi, analisis rerata perubahan menunjukkan bahwa suplementasi vitamin D tidak menyebabkan penurunan tekanan darah sistolik (D = -4,6(-25 - -0,5) mmHg pada kelompok kontrol dan D = -9,2 (-20 - -27) mmHg pada kelompok perlakuan; p = 0.109) dan tekanan darah diastolik secara bermakna (D = -7,2 (-16 - -2) mmHg pada kelompok kontrol dan D = -8,4 (-14,5 - -8,5) mmHg pada kelompok perlakuan; p=0,559). Suplementasi vitamin D dapat meningkatkan kadar 25(OH)D secara bermakna, tetapi tidak menurunkan tekanan darah sistolik dan diastolik secara bermakna pada lansia.

---

Hypertension is the most common cardiovascular disease, especially in the elderly. Previous studies have reported that vitamin D play a role in blood pressure. In elderly, serum 25(OH)D levels decrease due to lack of sun exposure and intake of food sources of vitamin D. Vitamin D deficiency can be prevented by supplementation. This is an experimental study with double-blind randomized placebo-controlled trial (RCT) on elderly subjects at the Tresna Werdha Budi Mulia 1 Social Institution from April until June 2023 to analyze the effect of vitamin D supplementation on serum 25(OH)D levels and blood pressure. Serum 25(OH)D levels were examined using Chemiluminescent Immunoassay (CLIA) method, blood pressure was checked using digital sphygmomanometer. Supplementation was given once per day for 8 weeks, control group was given a placebo while treatment group was given vitamin D3 supplementation at dose of 2000IU (insufficiency subjects) and 4000IU (deficiency subjects). A total of 62 research subjects aged 60-89 years (median 67 years) participated in this study and randomized into 30 control group subjects and 32 treatment group subjects. The increase in serum 25(OH)D levels in the control group was 23 ± 4,87 ng/mL to 27,3 ± 7,34 ng/mL (p = 0.000), the treatment group was 17,9 ± 4,38 ng/mL to 36,07 ± 9,84 ng/mL (p = 0.000). Data analysis showed that vitamin D supplementation significantly increased 25(OH)D levels in the treatment group compared to the control group (D = 4,2 ± 2,47 ng/mL for control group and D = 18,17 ± 5,46 ng/mL for treatment group; p = 0.000). The decrease in systolic blood pressure in the control group was 133,9(121 – 159,5) mmHg to 129,3(96 – 159) mmHg (p = 0.027), the treatment group was 135,3(121 - 180) mmHg to 126(101 - 153) mmgHg (p = 0.000). The decrease in diastolic blood pressure in the control group was 89,6(80 - 105) mmHg to 82,4(64 - 103) mmHg (p = 0.000), the treatment group was 89,2(81,5 – 98,5) mmHg to 80,8 (67 – 90) mmHg (p = 0.000). However, data analysis showed that vitamin D supplementation did not cause a significant reduction in systolic blood pressure (D = -4,6(-25 - -0,5) mmHg for control group and D = -9,2 (-20 - -27) mmHg for treatment group; p = 0.109) and diastolic blood pressure in the treatment group compared to the control group (D = -7,2 (-16 - -2) mmHg for control group and D = -8,4(-14,5 - -8,5) mmHg for treatment group; p = 0.559). Vitamin D supplementation significantly increase serum 25(OH)D levels, but not significantly reduce systolic and diastolic blood pressure in the elderly."